Please assess the completion status of the following clinical trial:

Trial Title: A Study of Duloxetine in Elderly Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have GAD based on diagnostic criteria and not suffer from an adjustment disorder or anxiety disorder not otherwise specified. Symptoms of GAD should not be situational in nature.~* Have a Mini Mental State Examination (MMSE) score of at least 24 at screening.~* Have a Clinical Global Impressions of Severity (CGI-Severity) score of greater than or equal to 4 at screening and randomization.~* Have a Covi Anxiety Scale (CAS) score of greater than or equal to 9, no item in the Raskin Depression Scale (RDS) may be \>3, and the CAS score must be greater than the RDS at screening.~* Have a Hospital Anxiety and Depression Scale (HADS) anxiety subscale score of greater than or equal to 10 at screening.~* Have a degree of understanding such that the participant can communicate intelligibly with the investigator and study coordinator.~* Are judged to be reliable to keep all appointments and able to swallow all required medication without opening or crushing.~Exclusion Criteria:~* Have any current and primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revised (DSM-IV TR) Axis I diagnosis other than GAD, with the exception of comorbid social phobia or specific phobia.~  * major depressive disorder (MDD) within the past 6 months, or~ * panic disorder, posttraumatic stress disorder (PTSD), or an eating disorder within the past year, or~ * obsessive compulsive disorder (OCD), bipolar affective disorder, psychosis, factitious disorder, or somatoform disorders during their lifetime.~* The presence of an Axis II disorder, or history of antisocial behavior, or participants who, in the opinion of the investigator, are poor medical or psychiatric risks for study compliance.~* Have organic mental disorder or mental retardation diagnosis.~* Use of benzodiazepine within 14 days prior to randomization.~* Are judged clinically to be at serious risk of harm to self or others.~* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.~* Have previously completed or withdrawn from this study or any other study investigating duloxetine or have previously been treated with duloxetine within the past year or participants with a lack of response or intolerability to duloxetine (for any approved indication) at a clinically appropriate dose for a minimum of 4 weeks.~* Have a history of alcohol or any psychoactive substance abuse or dependence within the past 6 months.~* Excessively use caffeine, in the opinion of the investigator.~* Have a positive urine drug screen (UDS) for any substances of abuse at screening.~* Have a serious medical illness.~* Have any acute liver injury or severe cirrhosis.~* Have an abnormal thyroid-stimulating hormone (TSH) concentrations.~* Have initiated psychotherapy or changed intensity of psychotherapy or other non-drug therapies (such as acupuncture or hypnosis) within 6 weeks prior to enrollment or at any time during the study.~* Have taken any excluded medication within 7 days prior to randomization.~* Have been treated with a monoamine oxidase inhibitor (MAOI) or fluoxetine within 30 days of randomization or potentially need to use an MAOI during the study or within 5 days of discontinuation of study drug.~* Exhibit a lack of response of the current episode of GAD to 2 or more adequate trials of antidepressants, benzodiazepines, or other anxiolytics at a clinically appropriate dose for a minimum of 4 weeks.~* Have a history of severe allergies, hypersensitivity to duloxetine or to any of the inactive ingredients; multiple adverse drug reactions; transcranial magnetic stimulation (TMS); history of seizures; or history of psychosurgery or electroconvulsive therapy (ECT) within 12 months.~* Have discontinued hormone replacement therapy within the previous 3 months.~* Have uncontrolled narrow-angle glaucoma.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine 30 milligrams (mg) -120 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).